Research Topics

Francesco Dentali

Summary

Country: Italy

Publications

  1. Dentali F, Gianni M, Lussana F, Squizzato A, Cattaneo M, Ageno W. Polymorphisms of the Z protein protease inhibitor and risk of venous thromboembolism: a meta-analysis. Br J Haematol. 2008;143:284-7 pubmed publisher
    ..Five studies involving 5000 patients were included. R67X and W303X mutations of Serpina10 were not associated with increased VTE risk (OR 1.63; 95% CI 0.84, 3.16 and OR 1.21; 95% CI 0.29, 4.98 respectively). ..
  2. Dentali F, Ageno W, Becattini C, Galli L, Gianni M, Riva N, et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res. 2010;125:518-22 pubmed publisher
    ..27 and OR 1.80 respectively). The prevalence of incidental PE is clinically relevant. Future studies are necessary to properly evaluate the clinical history of these patients. ..
  3. Dentali F, Ageno W, Rancan E, Donati A, Galli L, Squizzato A, et al. Seasonal and monthly variability in the incidence of venous thromboembolism. A systematic review and a meta-analysis of the literature. Thromb Haemost. 2011;106:439-47 pubmed publisher
    ..Future studies are needed to better clarify the mechanisms behind this pattern. ..
  4. Dentali F, Riva N, Crowther M, Turpie A, Lip G, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381-91 pubmed publisher
    ..NOACs are associated with an overall clinical benefit compared with vitamin K antagonists. Additional research is required to confirm these findings outside the context of randomized trials. ..
  5. Dentali F, Fantoni C. Is it reasonable to use a lower DOAC dose in some patients with VTE? NO. Intern Emerg Med. 2017;12:565-567 pubmed publisher
    ..In light of this evidence, the use of lower DOAC dose in patients with VTE does not appear reasonable and may be potentially dangerous. ..
  6. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost. 2008;99:675-82 pubmed publisher
    ..The pooled OR for PVT was 1.90 (95%CI: 1.25, 2.90) in patients with FVL and 4.48 (95%CI: 3.10, 6.48) in patients with PTM. In conclusion, PVT is associated with the presence of FVL and PTM in Western Europe. ..

Detail Information

Publications6

  1. Dentali F, Gianni M, Lussana F, Squizzato A, Cattaneo M, Ageno W. Polymorphisms of the Z protein protease inhibitor and risk of venous thromboembolism: a meta-analysis. Br J Haematol. 2008;143:284-7 pubmed publisher
    ..Five studies involving 5000 patients were included. R67X and W303X mutations of Serpina10 were not associated with increased VTE risk (OR 1.63; 95% CI 0.84, 3.16 and OR 1.21; 95% CI 0.29, 4.98 respectively). ..
  2. Dentali F, Ageno W, Becattini C, Galli L, Gianni M, Riva N, et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res. 2010;125:518-22 pubmed publisher
    ..27 and OR 1.80 respectively). The prevalence of incidental PE is clinically relevant. Future studies are necessary to properly evaluate the clinical history of these patients. ..
  3. Dentali F, Ageno W, Rancan E, Donati A, Galli L, Squizzato A, et al. Seasonal and monthly variability in the incidence of venous thromboembolism. A systematic review and a meta-analysis of the literature. Thromb Haemost. 2011;106:439-47 pubmed publisher
    ..Future studies are needed to better clarify the mechanisms behind this pattern. ..
  4. Dentali F, Riva N, Crowther M, Turpie A, Lip G, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381-91 pubmed publisher
    ..NOACs are associated with an overall clinical benefit compared with vitamin K antagonists. Additional research is required to confirm these findings outside the context of randomized trials. ..
  5. Dentali F, Fantoni C. Is it reasonable to use a lower DOAC dose in some patients with VTE? NO. Intern Emerg Med. 2017;12:565-567 pubmed publisher
    ..In light of this evidence, the use of lower DOAC dose in patients with VTE does not appear reasonable and may be potentially dangerous. ..
  6. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost. 2008;99:675-82 pubmed publisher
    ..The pooled OR for PVT was 1.90 (95%CI: 1.25, 2.90) in patients with FVL and 4.48 (95%CI: 3.10, 6.48) in patients with PTM. In conclusion, PVT is associated with the presence of FVL and PTM in Western Europe. ..